Stipple Bio secured $100M in financing to support discovery of new cancer drug targets. The capital should extend R&D runway and accelerate its target-discovery platform and preclinical programs, reducing near-term funding risk for the company.
Stipple Bio secured $100M in financing to support discovery of new cancer drug targets. The capital should extend R&D runway and accelerate its target-discovery platform and preclinical programs, reducing near-term funding risk for the company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
